Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

The ACVSB felt that there was no case for using surrogate tests for Non-A Non-B Hepatitis.

  • Read more about The ACVSB felt that there was no case for using surrogate tests for Non-A Non-B Hepatitis.

Dr Gunson presented a summary of results of the study on Alanine Amino-Transferase and Hepatitis B Core Screening of Blood Donations for an ACVSB meeting.

  • Read more about Dr Gunson presented a summary of results of the study on Alanine Amino-Transferase and Hepatitis B Core Screening of Blood Donations for an ACVSB meeting.

The Advisory Committee on Transfusion Transmitted Diseases agreed that Dr Gunson's report, both Chiron's test (now called the anti-HCV test) and NANBH surrogate screening, should be used as the basis for a paper to be submitted to the ACVSB.

  • Read more about The Advisory Committee on Transfusion Transmitted Diseases agreed that Dr Gunson's report, both Chiron's test (now called the anti-HCV test) and NANBH surrogate screening, should be used as the basis for a paper to be submitted to the ACVSB.

Dr Gunson recommended that the routine introduction of non-specific tests for HCV should be deferred unless necessary to acquire product licences.

  • Read more about Dr Gunson recommended that the routine introduction of non-specific tests for HCV should be deferred unless necessary to acquire product licences.

It was agreed at the meeting of the Advisory Committee on the Virological Safety of Blood that the use of Chiron or surrogate testing for HCV would be influenced by Chiron data once released.

  • Read more about It was agreed at the meeting of the Advisory Committee on the Virological Safety of Blood that the use of Chiron or surrogate testing for HCV would be influenced by Chiron data once released.

A paper provided to ACVSB members explained it was too early to report on the UKBTS study into surrogate testing and conclusions would not be drawn until the result of the Chiron tests were known.

  • Read more about A paper provided to ACVSB members explained it was too early to report on the UKBTS study into surrogate testing and conclusions would not be drawn until the result of the Chiron tests were known.

At the first ACVSB meeting a paper on surrogate testing for NANBH was considered, although a final decision would have to await the results of further research.

  • Read more about At the first ACVSB meeting a paper on surrogate testing for NANBH was considered, although a final decision would have to await the results of further research.

Dr Gunson explained to the NBTS/CBLA Liaison Committee the NBTS's view that the introduction of ALT testing was unnecessary. It was agreed that the issue
would be considered further at another meeting

  • Read more about Dr Gunson explained to the NBTS/CBLA Liaison Committee the NBTS's view that the introduction of ALT testing was unnecessary. It was agreed that the issue would be considered further at another meeting

At the first meeting of the ACTTD it was agreed that no recommendation to introduce ALT testing would be made until the multi-centre study was completed. It was noted that surrogate screening might be introduced in response to the position taken in other countries in relation to plasma products.

  • Read more about At the first meeting of the ACTTD it was agreed that no recommendation to introduce ALT testing would be made until the multi-centre study was completed. It was noted that surrogate screening might be introduced in response to the position taken in other countries in relation to plasma products.

At meeting of SNBTS directors, Dr Gunson explained that Chiron had agreed to test 1,000 randomly selected samples from the multi-centre study. The Scottish transfusion directors confirmed they would not start surrogate testing unless and until it was supported by the Department of Health and SHHD,

  • Read more about At meeting of SNBTS directors, Dr Gunson explained that Chiron had agreed to test 1,000 randomly selected samples from the multi-centre study. The Scottish transfusion directors confirmed they would not start surrogate testing unless and until it was supported by the Department of Health and SHHD,

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 689
  • Page 690
  • Page 691
  • Page 692
  • Current page 693
  • Page 694
  • Page 695
  • Page 696
  • Page 697
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.